$PVCT Provectus Biopharmaceuticals’ PV-10 Clinical

New Post Public Reply Private Reply Replies (0) Message Board
fitzkarz
$PVCT

Provectus Biopharmaceuticals’ PV-10 Clinical Data on Melanoma Now Available for European Society for Medical Oncology 2014 Congress

Provectus Biopharmaceuticals, Inc. (NYSE MKT VCT) (http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company (“Provectus”), announced today that the abstract entitled, "Subgroup efficacy in patients receiving intralesional rose bengal to all existing melanoma in phase II study PV-10-MM-02," to be presented at the European Society for Medical Oncology 2014 Congress, is now available at https://www.webges.com/cslide/library/esmo/br...t#9faD03sJ.

The ESMO 2014 Congress in Madrid, Spain, runs from September 26-30, 2014. This poster presentation will be held on Sunday, September 28, 2014, beginning at 12:45 pm local time, presented by Sanjiv S. Agarwala, MD, of St. Luke’s Hospital and Health Network, Bethlehem, PA.

Dr. Craig Dees, PhD, CEO of Provectus, said, "We are very pleased that these subgroup data will be presented at ESMO this year, and we are glad that our principal investigator Dr. Agarwala will be available to discuss this work with attendees.”

PV-10, a 10% solution of Rose Bengal that is currently being investigated as a potential cancer therapeutic, is designed for injection into solid tumors (intralesional administration).

About the European Society for Medical Oncology

The European Society for Medical Oncology (ESMO) is the leading European professional organization committed to advancing the specialty of medical oncology and promoting a multidisciplinary approach to cancer treatment and care.

ESMO’s mission is to advance cancer care and cure through fostering and disseminating good science that leads to better medicine and determines best practice.

ESMO’s scientific journal, Annals of Oncology, ranks among the top clinical oncology journals worldwide. ESMO events are the meeting place in Europe for medical oncologists to update their knowledge, to network and to exchange ideas.

To find out more about ESMO, please visit: www.esmo.org.

About Provectus Biopharmaceuticals, Inc.

Provectus Biopharmaceuticals, Inc., specializes in developing oncology and dermatology therapies. PV-10, its novel investigational drug for cancer, is designed for injection into solid tumors (intralesional administration), thereby reducing potential for systemic side effects. Its oncology focus is on melanoma, breast cancer and cancers of the liver. The Company has received orphan drug designations from the FDA for its melanoma and hepatocellular carcinoma indications. PH-10, its topical investigational drug for dermatology, is undergoing clinical testing for psoriasis and atopic dermatitis. Provectus has completed phase 2 trials of PV-10 as a therapy for metastatic melanoma, and of PH-10 as a topical treatment for atopic dermatitis and psoriasis. Information about these and the Company’s other clinical trials can be found at the NIH registry, www.clinicaltrials.gov. For additional information about Provectus, please visit the Company’s website at www.pvct.com or contact Porter, LeVay & Rose, Inc.

FORWARD-LOOKING STATEMENTS: This release contains “forward-looking statements” as defined under U.S. federal securities laws. These statements reflect management’s current knowledge, assumptions, beliefs, estimates, and expectations and express management’s current views of future performance, results, and trends and may be identified by their use of terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “will,” and other similar terms. Forward-looking statements are subject to a number of risks and uncertainties that could cause our actual results to materially differ from those described in the forward-looking statements. Readers should not place undue reliance on forward-looking statements. Such statements are made as of the date hereof, and we undertake no obligation to update such statements after this date.

Risks and uncertainties that could cause our actual results to materially differ from those described in forward-looking statements include those discussed in our filings with the Securities and Exchange Commission (including those described in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2013, and in our Quarterly Reports on Form 10-Q for the quarters ended March 31, 2014, and June 30, 2014), and the following:

• our determination, based on guidance from the FDA, whether to proceed with or without a partner with a phase 3 trial of PV-10 to treat locally advanced cutaneous melanoma and the costs associated with such a trial if it is necessary;
• our determination whether to license PV-10, our melanoma drug product candidate, and other solid tumors such as liver cancer, if such licensure is appropriate considering the timing and structure of such a license, or to commercialize PV-10 on our own to treat melanoma and other solid tumors such as liver cancer;
• our ability to license our dermatology drug product candidate, PH-10, on the basis of our phase 2 atopic dermatitis and psoriasis results, which are in the process of being further developed in conjunction with mechanism of action studies; and
• our ability to raise additional capital if we determine to commercialize PV-10 and/or PH-10 on our own, although our expectation is to be acquired by a prospective pharmaceutical or biotech concern prior to commercialization.

Copyright Business Wire 2014

Source: Business Wire (September 24, 2014 - 6:00 AM EDT)

News by QuoteMedia
I'm in it to win it!

NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.

I was born with it, I'm truly blessed!


Alway's searching for winners'
937206596_images.jpg
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Industrial Air Compressors: Fix, Rebuild, or Replace

Updated Category News Views 90

A compressor’s ugliest invoice is rarely the one from the service technician. It is the one nobody sees at first: a stalled production line, missed output, overtime, wasted electricity, and a maintenance crew chasing the same machine again next month. Pam Mahood of Waterloo, Iowa-based Compressed Air & Equipment Co. puts the decision where it belongs—not on the price...

Continue Reading
Rosenblatt Book Puts Vegas Casino Blind Spots on Display

Updated Category News Views 143

A locked casino floor is supposed to make secrets expensive. That is why the pitch behind ROSENBLATT lands with a little more weight than the usual Vegas chest-thumping: the coming memoir says Darryl Rosenblatt became a million-dollar gambler while using none of his own money, and that casino operators did not grasp the full shape of what had happened for years. Take a...

Continue Reading
KONST Pitches Asia GPU Uptime as AI Demand Gets Real

Updated Category News Views 93

GPU racks are easy to admire when the lights are on; keeping them useful at 3 a.m. is where the bruises show. KONST arrived at SC26 in Chicago with a sensible pitch for an AI-infrastructure market that is getting less impressed by shiny hardware lists and more obsessed with whether the thing actually works. Its theme, “24/7 GPUs Delivered in Asia,” puts the emphasis...

Continue Reading
Minnesota Giving Record Signals a Stressed Safety Net

Updated Category News Views 63

Thirty-eight million dollars landing in one day is no small civic heartbeat. Minnesota’s Give to the Max Day brought in a record $38.4 million in 2026 for nearly 6,000 nonprofits and schools, edging past the $37.8 million raised in 2025. More than 65,000 people gave. That deserves a clear-eyed nod, not a cynical shrug. Still, the number carries two messages at once. It...

Continue Reading
Six LIFE Photographers Bring History Into Florida Focus

Updated Category News Views 55

Seventy photographs can make a pretty loud argument when the historical record has been this lopsided. The Ashley Gibson Barnett Museum of Art at Florida Southern College has brought LIFE: Six Women Photographers to Lakeland, and it deserves more than the usual polite nod given to a traveling museum show. Open since November 14, 2026, and running through March 7, 2027,...

Continue Reading
Caliway's China Clearance Speeds CBL-514's Next Test

Updated Category News Views 165

China's regulator moved faster than the calendar, and that is the one detail worth circling in red ink. Caliway Biopharmaceuticals has received authorization from the Center for Drug Evaluation under China's National Medical Products Administration to begin CBL-0102, its China study of injectable fat-reduction candidate CBL-514. For a clinical-stage company, an...

Continue Reading
Webster First Takes Aim at the Youth Money Literacy Gap

Updated Category News Views 39

Money mistakes get expensive long before anyone calls them mistakes. That is the uncomfortable point beneath Webster First Federal Credit Union CEO John Thomasian's November 20, 2026 discussion of financial literacy: plenty of young adults are entering the real financial world with a card, a loan offer, and a phone full of banking apps, but no sturdy framework for using...

Continue Reading
Millrose Lawsuit Puts Disclosure Discipline in Focus

Updated Category News Views 64

A supposedly clean homesite-option story has wandered into the legal weeds, and that is exactly where investors need to slow down. A shareholder class action against Millrose Properties alleges the company painted one business model for the market while pursuing a materially different one behind the curtain. That allegation has not been proven in court, and anybody...

Continue Reading
Epilepsy Campaign Puts Patient Voices Before Investors

Updated Category News Views 18

An epilepsy diagnosis can turn ordinary family routines into a maze overnight, which is why awareness work deserves more than the usual polite nod and a colored ribbon. Mediaplanet's national Epilepsy Awareness campaign, launched November 20, 2026, brings the subject into a USA TODAY print insert and related digital coverage during Epilepsy Awareness Month. That reach...

Continue Reading
Childcare Scale Makes Its Case, With Caveats Attached

Updated Category News Views 49

Childcare’s math is brutal before anybody starts arguing over ownership. Families need dependable hours, educators deserve better pay, and operators must keep buildings safe, staffed and open without pricing working parents clean out of the market. That is why this new Tyton Partners review of multi-site providers deserves a fair look, even if nobody should mistake a...

Continue Reading

Top 5 Most Recently Viewed Articles

AlidaBio Unveils New Platform to Revolutionize RNA Research

Updated Category News Views 249

Introducing the EpiPlex™ Platform Alida Biosciences, known for its innovative tools in epigenomic research, has officially launched its EpiPlex™ platform. This groundbreaking technology stands out by being the first to detect and quantify multiple RNA modifications concurrently, using short-read sequencing. Alongside this platform, the company has introduced the...

Continue Reading
Kootenay Silver Welcomes Ron Miller to Its Board of Directors

Updated Category News Views 149

Kootenay Silver Welcomes Ron Miller to Its Board of Directors Kootenay Silver Inc. (TSXV: KTN) (OTCQX: KOOYF) proudly announces the appointment of Ron Miller as a new director. With over 30 years of rich experience in public accounting and the mining industry, Mr. Miller brings a wealth of expertise to the company. Previously, he was a Partner and National Leader in...

Continue Reading
Estee Lauder Options Trading Insights and Market Position

Updated Category News Views 48

Unusual Options Activity for Estee Lauder Cos Recently, a noticeable shift has occurred in the options trading landscape for Estee Lauder Cos (NYSE: EL). Our analysis has identified some significant bearish actions from prominent financial investors targeting this beauty giant. Out of a thorough review of options trading history for Estee Lauder Cos, a total of ten...

Continue Reading
Roche's Innovative PCR Test Enhances Vaginitis Diagnosis for Women

Updated Category News Views 217

Roche Introduces Groundbreaking PCR Test for Vaginitis Roche has recently launched an innovative PCR test aimed at enhancing the diagnostic accuracy for women dealing with vaginitis. This new assay, named cobas® BV/CV (Bacterial Vaginosis/Candida Vaginitis), harnesses the power of advanced molecular technology to identify specific bacteria and yeast linked to these...

Continue Reading
Regan Capital Offers New Fee Structure for Income Fund Investment

Updated Category News Views 155

Regan Capital Announces Fee Reduction for Its Income Fund Regan Capital, a prominent investment firm overseeing more than $2.2 billion in assets, has made a significant announcement that is sure to capture the attention of investors. The firm revealed a fee reduction for its acclaimed Regan Total Return Income Fund, known by its ticker RCIRX. This open-ended mutual fund...

Continue Reading